Lois Atkins
Lois Atkins is a principal consultant, CMC regulatory affairs at Eli Lilly and Company
Articles
Quality by Design for Biotechnology Products—Part 3
Sally Anliker;Jennifer Mercer;Tim Schofield;Bruce Meiklejohn;Mark Schenerman;Samantha Sheridan;Taruna Arora;Stefanie Pluschkell;Meg Casais;Mark Rosolowsky;Joseph Mezzatesta;Paul Tsang;Jim Precup;Stuart Feldman;Lois Atkins;Bernerd McGarvey;Tony Lubiniecki;Paul Smock;Jutta Look;Anurag S. Rathore
January 1st 2010Regulatory flexibility can make continuous improvement possible.
Quality by Design for Biotechnology Products—Part 1
Sally Anliker;Jennifer Mercer;Tim Schofield;Bruce Meiklejohn;Mark Schenerman;Samantha Sheridan;Taruna Arora;Stefanie Pluschkell;Meg Casais;Mark Rosolowsky;Joseph Mezzatesta;Paul Tsang;Jim Precup;Stuart Feldman;Lois Atkins;Bernerd McGarvey;Tony Lubiniecki;Paul Smock;Jutta Look;Anurag S. Rathore
November 1st 2009First in a three-part series that discusses the complexities of QbD implementation in biotech product development.
Latest Updated Articles
Published: September 11th 2024 | Updated: September 18th 2024
CPHI Pharma Award Finalists Announced for 2024
Published: March 27th 2024 | Updated: June 28th 2024
AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product
Published: October 28th 2024 | Updated: November 22nd 2024
Discovery to Commercialization: The Right Partnerships are Key to Streamlined Drug Development
Published: November 15th 2024 | Updated: November 22nd 2024
Solving Challenges with AAV Aggregate Analysis Using a Novel Size Exclusion Particle to Determine CQAs
Published: October 28th 2024 | Updated: November 22nd 2024
Cell-based phenotypic screening with Incucyte® Live-Cell Analysis Systems
Published: October 22nd 2024 | Updated: November 22nd 2024
Optimizing cGMP Facility Design Space with a Hybrid Approach
